Scholar Rock Holding Corp. Stock News

CAMBRIDGE, Mass.

Shares are down 70% thus far in 2022. TOPAZ data update for apitegromab in SMA was encouraging (as reflected in increases in HFMSE and RULM scores).

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the company will present new data at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022.

The consensus price target hints at a 246.1% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward t

A venture capital group significantly increased its stake in the company.

The consensus price target hints at a 394.4% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward t

Scholar Rock Holding Corp (NASDAQ: SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atroph

Scholar Rock Holding Corporation (SRRK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in rai

Scholar Rock Holding Corp (NASDAQ: SRRK) plans to reduce its overall headcount by 25%, and its Chief Medical Officer Yung Chyung will step down by the end of June.  "Parting with employees who hav

Scholar Rock Holding Corporation (SRRK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving hig

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a poster presentation at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 13 - 16.

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament